A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery
Recruitment status was: Active, not recruiting
Pulmonary Wedge Resection
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery|
- Effect of perioperative statin use on in-hospital morbidity after thoracic cancer surgery
- Effect of perioperative statin use on the development of Major Adverse Pulmonary Events (MAPE) [ Time Frame: 30 days after initial surgery ]Includes acute lung injury, acute respiratory distress syndrome, pulmonary embolus, respiratory failure requiring mechanical ventilation and pneumonia
- Effect of perioperative statin use and the development of Major Adverse Cardiac Events (MACE) [ Time Frame: 30 days after initial surgery ]Includes atrial fibrillation, other arrhythmia, myocardial infarction and congestive heart failure.
- Effect of perioperative statin on mortality associated with cancer recurrence following thoracic cancer surgery.
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||July 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
|Thoracic sugery statins|
|Thoracic surgery non-statins|
Statins are well established for the use of primary and secondary prevention of cardiovascular disease. Moreover, there is increasing evidence that statins have numerous effects separate from their lipid lowering properties—pleiotropic effects. These pleiotropic effects, including a reduction in the inflammatory response and improved endothelial function, may improve perioperative outcomes via modulation of the surgical stress response. Improved perioperative outcomes have been demonstrated in patients undergoing vascular, cardiac and non-cardiovascular surgery. Specific to the thoracic surgery population, statin use has been reported to reduce the incidence of atrial fibrillation.
Statins, via inhibition of the rate limiting step of the mevalonate pathway, have also sparked interest in their potential anticancer effects as well as in cancer prevention. There is some evidence for anticancer effects of statins in patients with esophageal and lung cancer. Additionally, other agents with known anti-inflammatory effects also point to the potential for improved outcome in cancer patients. In this regard, aspirin use is reported to associate with prolonged survival in breast cancer patients, while perioperative use of anti-inflammatory agents (COX-II inhibitor use and lung cancer; aprotinin use and mesothelioma; aprotinin use and esophageal cancer) is associated with improved postoperative survival. Moreover, the use of regional analgesia is commonly employed in the thoracic surgery population and has been associated with attenuation of metastasis and improvement in recurrence rates for some types of cancers.
In a prospective pilot study of patients undergoing elective thoracic surgery, a collaborative member of our group recently found that patients suffering postoperative complications had poorer endothelial function, as measured by flow mediated dilation. Those patients with poorer endothelial function had greater wound healing complications (6% vs. 0%, p=0.01), longer ICU length of stay (4 vs. 0.9 days, p=0.02), and longer hospital length of stay (14 vs. 6.9 days, p=0.01). Although this pilot study was underpowered to demonstrate a significant correlation between Brachial Artery Reactivity Testing (BART) derived endothelial function and "all" postoperative complications, it provides hypothesis generating data and supports the hypothesis that statins, as modulators of endothelial function, may have a role in improving postoperative outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01169051
|Principal Investigator:||Justin Sandall, D.O.||Vanderbilt University|
|Study Director:||Mias Pretorius, M.D.||Vanderbilt University|